HCPCS code A9569: Tc-99m labeled WBCs, per study dose2026 Medicare rate & RVUs

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What A9569 covers

This code identifies a study dose of technetium-99m exametazime labeled to the patient’s own white blood cells. A nuclear medicine team collects a blood sample, labels the white cells outside the body, and returns them to the patient before imaging. The study can help locate suspected infection or inflammation, including osteomyelitis, an infected prosthesis, or an otherwise difficult-to-localize infection. A9569 identifies the radiopharmaceutical dose, not image acquisition or interpretation.

The physician fee schedule payment status is C, or carrier priced: CMS publishes no national payment, and the Medicare Administrative Contractor sets payment for each claim. HCPCS assigns other contractor pricing, so the Medicare contractor sets payment. Coverage is left to that contractor’s judgment. The code is reported per study dose, rather than by millicurie or image count. Nuclear medicine providers typically report it when furnishing the labeled-cell dose for the study.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where A9569 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

A9569 rates by state

Office rate range in each state. Select a state to see its payment localities.

How the A9569 rate is calculated

Each of A9569’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for A9569

A9569 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

A9569 compared with similar codes

How to choose

A9570Indium-111 WBCPer study dose

Choose A9569 for technetium-99m exametazime labeled white blood cells; A9570 identifies indium-111 labeled autologous white blood cells.

A9560Labeled red blood cellsPer study dose

A9560 identifies technetium-99m labeled red blood cells, not the patient’s labeled white blood cells used for leukocyte imaging.

78803Tumor SPECTSingle body area

A9569 identifies the radiopharmaceutical study dose. CPT 78803 represents tomographic imaging when SPECT is performed.

Codes related to A9569

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates